Irene Moreno-Candilejo

12PUBLICATIONS
145CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 21, 2026
Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Mar 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Francois Ghiringhelli, Richard Kim, Teresa Macarulla

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|Mar 17, 2025
A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Johann S de Bono, Anja Williams, Ignacio Melero

Pageof 2

Frequent Collaborators

4 joint publications

Ignacio Melero

4 joint publications

Emiliano Calvo

4 joint publications

Reinhard Dummer

2 joint publications

Jorge Esteban-Villarrubia